Here is Matt Lowdon‘s Monday morning deal summary for last week in medical devices and biotechnology. Congratulations to all those involved and let us know if we missed anything.
🔔Third Rock Ventures-backed Merida Biosciences launches with $121M series A to fund autoimmune pipeline
🔔Puzzle Medical Devices® Inc. raises $30M for heart pump technology.
🔔As KalVista Pharmaceuticals, Inc. Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has sold the Japanese rights to the drug to Kaken Pharmaceutical Co Ltd for $11 million upfront.
🔔U.K.-based Epsilogen Ltd has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer antibody company.”
🔔Berlin-based REMATIQ, an AI-native platform for automated product compliance in MedTech, has raised €5.4 million in a Seed funding round to develop its AI technology,
🔔GSK pens $2.5B pact for ABL Bio Inc.‘s tech to help antibodies bypass blood-brain barrier
🔔Aelius Biotech, a Newcastle, UK-based biotech company providing laboratory gut models, raised £750K in funding.
🔔F-star Therapeutics charts new path, splitting from invoX after 2023’s $161M acquisition
🔔Stroke tech developers Kandu Health™, Neurolutions combine with $30M in new funding
🔔Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, following the FDA’s approval of its multi-cancer companion diagnostic test last autumn.
🔔TIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development.